SCHEMBL3789

SCHEMBL3789

N->[Pt](<-N)(Cl)Cl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10865376 0.93
Hydrochloric Acid SCHEMBL892718 0.93
Hydrochloric Acid SCHEMBL3195023 0.93
SCHEMBL177804 0.83
SCHEMBL2519937 0.83
SCHEMBL8944307 0.83
SCHEMBL1068879 0.83
SCHEMBL5834033 0.83
Hydrochloric Acid SCHEMBL5542472 0.77
Hydrochloric Acid SCHEMBL5548689 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 305354 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260144783-A1 COMPOSITION FOR PREVENTING OR TREATING PERIPHERAL NEUROPATHY, CONTAINING ISOQUINOLINE DERIVATIVE AS ACTIVE INGREDIENT ALTMEDICAL CO., LTD. (KR) 2026-05-28 US claimed
EP-4747388-A1 RECOMBINANT BACTERIAL CELL CAPABLE OF EXPRESSING A HETEROLOGOUS EXTRACELLULAR MATRIX (ECM) DEGRADING POLYPEPTIDE USING A TUMOUR-INDUCIBLE PROMOTER NEOBE THERAPEUTICS LTD (GB) 2026-05-27 EP claimed
EP-3607938-B1 PHARMACEUTICAL COMPOSITION SOVIC BRKICIC LJILJANA (HR) 2026-05-27 EP claimed
EP-4746899-A1 TREATMENT OF CANCER PATIENTS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES IN COMBINATION WITH TROP-2 TARGETING ADC Iovance Biotherapeutics, Inc. (US) 2026-05-27 EP claimed
EP-4747263-A1 LIPID NANOPARTICLES AND USES THEREOF University of Connecticut (US) 2026-05-27 EP claimed
EP-4747408-A1 DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER GENENTECH, INC. (US) 2026-05-27 EP claimed
EP-4746898-A2 IDENTIFICATION OF SEQUENCE VARIANTS OF THE ERVMER34-1 SEQUENCE FAMILY AND USE IN ANTI-CANCER THERAPIES The United States of America, as represented by the Secretary, Department of Health and Human Services (US) 2026-05-27 EP claimed
EP-4748859-A2 CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF The Regents of the University of California (US) 2026-05-27 EP claimed
CN-115491690-B Hydrogen evolution reaction catalyst and preparation method and application thereof WUHAN HIMALAYA PHOTOELECTRIC TECHNOLOGY Co.,Ltd. (CN) 2026-05-26 CN claimed
CN-122075438-A Synergistic anticancer application of redox responsive coacervate delivery chrysin and 3-methyladenine 2026-05-26 CN claimed
US-4536386-A HIGH DOSAGE OF METOCLOPRAMIDE A. H. ROBINS COMPANY, INC. (US) 1985-08-20 US claimed
EP-0120907-A1 PHARMACEUTICAL PREPARATIONS FOR USE IN ANTITUMOUR THERAPY Aston Molecules Limited (GB) 1984-10-10 EP claimed
EP-0110955-A1 BRAIN-SPECIFIC DRUG DELIVERY. UNIV FLORIDA (US) 1984-06-20 EP claimed
US-4451447-A CISPLATIN, ETHYLENE OXIDE ADDUCT, SODIUM CHLORIDE AND WATER BRISTOL-MYERS COMPANY (US) 1984-05-29 US claimed
WO-1984001506-A1 PHARMACEUTICAL PREPARATIONS FOR USE IN ANTITUMOUR THERAPY UNIV BIRMINGHAM (GB) 1984-04-26 WO claimed
US-4426372-A SULFIRAM OR DIALKYL DITHIOCARBAMATE REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 1984-01-17 US claimed
WO-1983003968-A1 BRAIN-SPECIFIC DRUG DELIVERY UNIVERSITY OF FLORIDA (US) 1983-11-24 WO claimed
US-4322391-A DISSOLVING IN AN ORGANIC AMIDE, HYDROCHLORIC ACID SOLUTION, PRECIPITATION AND FILTRATION BRISTOL-MYERS COMPANY (US) 1982-03-30 US claimed
US-4310515-A INJECTABLE ANTITUMOR AGENT BRISTOL-MYERS COMPANY (US) 1982-01-12 US claimed
US-4302446-A MICROCRYSTALLINE CISPLATEN ANTINEOPLASM AGENT BRISTOL-MYERS COMPANY (US) 1981-11-24 US claimed